$ELTX

Elicio Therapeutics, Inc.

Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, including cancers with KRAS, BRAF and TP53 mutations. Its proprietary Amphiphile, or AMP, technology is designed to deliver therapeutic payloads to lymph nodes and stimulate T-cell responses. Elicio’s lead clinical candidate, ELI-002, is an off-the-shelf peptide immunotherapy targeting KRAS mutations; its seven-peptide formulation is being evaluated in a Phase 2 study for pancreatic cancer. Its preclinical candidates ELI-007 and ELI-008 target BRAF- and TP53-mutated cancers, respectively. Elicio also explores AMP applications in T-cell therapies and other immunotherapy approaches. It aims to develop and commercialize lymph node-targeted immunotherapies and pursue collaborations to advance its technology and pipeline. Elicio is headquartered in Boston, Massachusetts.

0
1
1

No SEC Form 4 filings for $ELTX in the last 30 days.

See all $ELTX insider activity →
Low

Elicio Therapeutics Stockholders Approve Directors and Auditor

Elicio Therapeutics (ELTX) held its annual meeting on November 12, 2026, with 66.74% of shares represented. Stockholders approved three directors and ratified Baker Tilly US as auditor. Analysts have mixed views, with a Buy rating and $21 target, while Spark's AI rates it Neutral due to financial performance and technical indicators.

Elicio Therapeutics, Inc. (ELTX): Submission of Matters to a Vote of Security Holders

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two

ELTX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ELTX (Elicio Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent ELTX coverage spans corporate actions, financial news and earnings.

What's driving ELTX

AlphAI scores every news story that mentions ELTX with an AI model for sentiment and relevance, and aggregates insider trades from Elicio Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ELTX

Score
$ELTXLowShareholder vote

Elicio Therapeutics, Inc. (ELTX): Submission of Matters to a Vote of Security Holders

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two

$ELTXHighEarnings

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and patients without prior radiation, enabling a

$ELTXMedAI 9/10

99% of evaluable treated patients showed immune responses to a cancer mutation. The trial missed its main goal.

Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.

$ELTXLowEarnings

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a

Related tickers